Wall Street analysts predict that Acer Therapeutics Inc (NASDAQ:ACER) will report ($0.69) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Acer Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.66) and the lowest estimate coming in at ($0.72). Acer Therapeutics reported earnings per share of ($1.24) in the same quarter last year, which suggests a positive year-over-year growth rate of 44.4%. The company is expected to announce its next quarterly earnings report on Friday, May 11th.
According to Zacks, analysts expect that Acer Therapeutics will report full-year earnings of ($3.22) per share for the current year, with EPS estimates ranging from ($3.72) to ($2.83). For the next financial year, analysts expect that the company will post earnings of ($2.55) per share, with EPS estimates ranging from ($2.81) to ($2.07). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Acer Therapeutics.
Acer Therapeutics (NASDAQ:ACER) last released its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.10).
Several research firms have commented on ACER. Zacks Investment Research cut Acer Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, March 9th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Acer Therapeutics in a research note on Friday, March 9th. Roth Capital began coverage on Acer Therapeutics in a research note on Monday, February 26th. They issued a “buy” rating and a $70.00 target price on the stock. William Blair began coverage on Acer Therapeutics in a research note on Friday, February 16th. They issued an “outperform” rating on the stock. Finally, ValuEngine cut Acer Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $60.00.
ACER stock traded down $0.24 during midday trading on Thursday, reaching $19.25. The company’s stock had a trading volume of 9,141 shares, compared to its average volume of 31,638. The company has a market cap of $148.37, a PE ratio of -4.87 and a beta of 2.54. Acer Therapeutics has a 12-month low of $5.69 and a 12-month high of $22.63.
Large investors have recently bought and sold shares of the business. Ardsley Advisory Partners acquired a new position in shares of Acer Therapeutics during the 4th quarter worth approximately $212,000. Stonepine Capital Management LLC acquired a new position in shares of Acer Therapeutics during the 4th quarter worth approximately $1,385,000. J. Goldman & Co LP acquired a new position in shares of Acer Therapeutics during the 4th quarter worth approximately $1,496,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Acer Therapeutics during the 4th quarter worth approximately $2,091,000. 7.41% of the stock is currently owned by hedge funds and other institutional investors.
About Acer Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.